Metformin Management in Patients Undergoing Colonoscopy

Introduction to Metformin Discontinuation

• The American Journal of Kidney Diseases recommends that patients with impaired renal function, particularly those with eGFR 30-60 mL/min/1.73 m², discontinue metformin before colonoscopy to minimize the risk of acute kidney injury and lactic acidosis 1
• Bowel preparation causes significant fluid losses that can precipitate acute renal impairment, creating a high-risk scenario for metformin accumulation in patients with reduced eGFR 1

Risk Stratification for Metformin Discontinuation

• For patients with normal renal function (eGFR ≥60 mL/min/1.73 m²), the American Diabetes Association and other guideline societies recommend stopping metformin the night before colonoscopy to minimize risks associated with the procedure 2 3
• The plasma half-life of metformin is approximately 6.2 hours, allowing for adequate clearance when stopped the night before the procedure 2

Perioperative Considerations

• The use of RAAS inhibitors (ACE inhibitors or ARBs) in patients undergoing colonoscopy increases the risk of acute kidney injury, and temporary suspension of these medications during bowel preparation is recommended 1
• Patients should be closely monitored for signs of dehydration, clinical instability, and renal function decline before restarting metformin after colonoscopy 1 2

Post-Procedure Management

• The American Society of Anesthesiologists and other guideline societies recommend waiting 48 hours after the procedure before restarting metformin, provided the patient's renal function is stable and they are adequately hydrated 2 3
• Before restarting metformin, it is crucial to confirm the patient's hydration status, oral intake, and renal function to minimize the risk of lactic acidosis 2

Special Considerations

• Phosphate-containing bowel preparations are contraindicated in patients with eGFR <60 mL/min/1.73 m² due to the risk of phosphate nephropathy and acute kidney injury 1
• Alternative bowel preparations, such as PEG-based solutions, should be used in patients with any degree of renal impairment to minimize risks 1